Signet Investment Advisory Group Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,752 shares of the company's stock after buying an additional 2,063 shares during the quarter. Johnson & Johnson accounts for 2.4% of Signet Investment Advisory Group Inc.'s portfolio, making the stock its 13th biggest holding. Signet Investment Advisory Group Inc.'s holdings in Johnson & Johnson were worth $4,768,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $33,000. Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson during the fourth quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the fourth quarter worth $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Up 0.4%
Shares of NYSE:JNJ opened at $163.65 on Friday. The stock's 50-day moving average price is $154.29 and its two-hundred day moving average price is $155.05. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The firm has a market cap of $393.75 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 2.19 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on JNJ. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday. UBS Group reiterated a "buy" rating and set a $190.00 price target (up from $180.00) on shares of Johnson & Johnson in a report on Thursday. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $172.87.
Read Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
